RefleXion, Telix partner on high-risk cancer treatments

By AuntMinnie.com staff writers

July 8, 2020 -- Radiation therapy equipment developer RefleXion Medical and radiopharmaceutical company Telix Pharmaceuticals are investigating the clinical utility of combining their technologies for improving treatments for high-risk prostate and aggressive kidney cancers.

Under their strategic collaboration agreement, the firms will assess the potential of several new Telix PET tracers, including gallium-68 prostate-specific membrane antigen-11 for prostate cancer and Zr-89-girentuximab for kidney cancer, for guiding RefleXion's biology-guided radiotherapy technology.


Copyright © 2020 AuntMinnie.com
 

To read this and get access to all of the exclusive content on AuntMinnie.com create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a AuntMinnie.com password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
What's this?
Sign in using your social networking
account:
(What's this?)


Forgot your password?
|
View our privacy policy.